Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shugo Yajima

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
International Urology and Nephrology|April 15, 2026
Reanalysis of LUNAR progression-free survival using reconstructed individual patient data: time-varying treatment effectsKenji Tanabe, Soichiro Yoshida, Motohiro Fujiwara, et al.
European Radiology|March 20, 2019
Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progressionShugo Yajima, Soichiro Yoshida, Taro Takahara, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
Journal of Medical Economics|March 6, 2026
Return on investment of national specific health guidance in Japan: an observational study using "Wellness-Star⋆" health insurance claims databaseTakuma Ueda, Akihiro Kakinuma, Masaru Kinugawa, et al.
JCO Clinical Cancer Informatics|June 30, 2026
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101Hiroshi Fukushima, Soichiro Yoshida, Shugo Yajima, et al.
Urology|July 15, 2026
Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY studyWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
Japanese Journal of Clinical Oncology|December 26, 2025
Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trialWei Chen, Soichiro Yoshida, Akihiro Hirakawa, et al.
BMC Cancer|October 5, 2023
Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria IIKenji Tanabe, Yasukazu Nakanishi, Naoya Okubo, et al.
Journal of Surgical Oncology|January 25, 2023
A novel predictive model for postoperative delirium using multiple geriatric screening factorsShugo Yajima, Yasukazu Nakanishi, Motokazu Sugimoto, et al.
Japanese Journal of Clinical Oncology|April 29, 2026
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
International Urology and Nephrology|April 15, 2026
Reanalysis of LUNAR progression-free survival using reconstructed individual patient data: time-varying treatment effectsKenji Tanabe, Soichiro Yoshida, Motohiro Fujiwara, et al.
European Radiology|March 20, 2019
Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progressionShugo Yajima, Soichiro Yoshida, Taro Takahara, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
Journal of Medical Economics|March 6, 2026
Return on investment of national specific health guidance in Japan: an observational study using "Wellness-Star⋆" health insurance claims databaseTakuma Ueda, Akihiro Kakinuma, Masaru Kinugawa, et al.
JCO Clinical Cancer Informatics|June 30, 2026
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101Hiroshi Fukushima, Soichiro Yoshida, Shugo Yajima, et al.
Urology|July 15, 2026
Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY studyWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
Japanese Journal of Clinical Oncology|December 26, 2025
Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trialWei Chen, Soichiro Yoshida, Akihiro Hirakawa, et al.
BMC Cancer|October 5, 2023
Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria IIKenji Tanabe, Yasukazu Nakanishi, Naoya Okubo, et al.
Journal of Surgical Oncology|January 25, 2023
A novel predictive model for postoperative delirium using multiple geriatric screening factorsShugo Yajima, Yasukazu Nakanishi, Motokazu Sugimoto, et al.
Japanese Journal of Clinical Oncology|April 29, 2026
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
Pageof 11